Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Insulet Corporation - Common Stock (NQ: PODD )

255.09 +10.42 (+4.26%)
Streaming Delayed Price Updated: 3:40 PM EDT, Mar 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Insulet Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Insulet to Announce First Quarter 2024 Financial Results on May 9, 2024
From Insulet Corporation
Via Business Wire
Large-Cap Stocks In Trouble: Here Are The 10 Worst Performers Over The Past 12 Months
Over the past 12 months, 10 Large-Cap stocks have underperformed all others. 
Via Talk Markets
5 Stocks To Buy On The Dip To Gain From The Wall Street Rally
Wall Street had a dream run in 2023, reversing the nightmare of 2022. The impressive bull run appears set to continue in 2024. Thus, here is a look at some stocks that may be worth buying on the dip... 
Via Talk Markets
Insulet Appoints Ana Maria Chadwick as Chief Financial Officer
From Insulet Corporation
Via Business Wire
Analyst Scoreboard: 5 Ratings For Insulet
Via Benzinga
Insulet: Q4 Earnings Insights
Via Benzinga
Why NASDAQ:PODD Is a Promising High-Growth Stock in the Midst of Consolidation.
INSULET CORP (NASDAQ:PODD) qualifies as a high growth stock and is consolidating. 
Via Chartmill
Are These 5 Undervalued Stocks Ready to Break Out?
Undervalued stocks Albemarle, Ionis, Insulet, Hess and Wynn beat earnings views, offering potential for investors to buy quality companies at discounted prices. 
Via MarketBeat
Insulet’s Randomized Controlled Trial (OP5-003) Demonstrates Omnipod® 5 Automated Insulin Delivery System is Superior to Pump Therapy
From Insulet Corporation
Via Business Wire
Insulet to Present Results from First Omnipod® 5 Randomized Controlled Trial (OP5-003) at the 17th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD)
From Insulet Corporation
Via Business Wire
Should you consider NASDAQ:PODD for growth investing?
Exploring INSULET CORP (NASDAQ:PODD)'s growth characteristics. 
Via Chartmill
Is It Time to Buy the S&P 500's 3 Worst-Performing February Stocks?
A handful of large-cap stocks are now on sale. The discount, however, doesn't necessarily make them worth buying. 
Via The Motley Fool
Topics Stocks
Exposures US Equities
Top Stocks Not Named Nvidia You Need To Know About In 2024: Here's What Investors Think About Them (Wall Street Vs. Reddit)
Nvidia Corp. is one of the leading top stocks with 60% gain in 2024, but other lesser-known names have outperformed. 
Via Benzinga
Surgery Partners Posts Weak Sales, Joins Kosmos Energy, Moderna And Other Big Stocks Moving Lower On Monday
U.S. stocks were slightly higher, with the Nasdaq Composite gaining around 10 points on Monday. Shares of Surgery Partners, Inc. (NASDAQ: SGRY) fell sharply during Monday’s session following weak... 
Via Benzinga
Topics Stocks
Exposures US Equities
INSULET CORP (NASDAQ:PODD) is a candidate for growth investors. Here's why.
Exploring growth characteristics of INSULET CORP (NASDAQ:PODD). 
Via Chartmill
DexCom: A Winner In Diabetes Management
Diabetes management and glucose monitoring solutions provider DexCom, Inc. recently released its fourth-quarter results, reporting $1.0 billion in revenue, up 27% year-over-year compared to $820... 
Via Talk Markets
Nasdaq, S&P 500 Set for Mixed Open After Nvidia Euphoria: Analyst Picks Major Market Catalyst This Year If There Are No Rate Cuts
After the exuberance seen on Thursday, investors may assess whether it was an irrational one, and futures trading on Friday reflects edginess. 
Via Benzinga
Topics Stocks
Exposures US Equities
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Insulet Reports Full Year 2023 Revenue Increase of 30% (30% Constant Currency1) and Fourth Quarter 2023 Revenue Increase of 38% Year-Over-Year (37% Constant Currency)
From Insulet Corporation
Via Business Wire
Nasdaq, S&P 500 Futures Jump As Nvidia Surge Raises 'FOMO' Rally Hopes: Analyst Tells Why Jobs Data Holds Key For Momentum
Market participants remain attentive to several factors shaping the day's trading landscape, including scheduled Fed speeches, weekly jobless claims data, and private-sector activity readings. 
Via Benzinga
Topics Economy Stocks
Exposures Interest Rates US Equities
Insulet to Present at The Raymond James & Associates 45th Annual Institutional Investors Conference
From Insulet Corporation
Via Business Wire
Earnings Scheduled For February 22, 2024
Companies Reporting Before The Bell • Indivior (NASDAQ:INDV) is likely to report quarterly earnings at $0.28 per share on revenue of $260.00 million. 
Via Benzinga
Insulet Announces CE Mark Approval of Omnipod® 5 Integration with Abbott FreeStyle Libre 2 Plus Sensor
From Insulet Corporation
Via Business Wire
5 top healthcare stocks for earnings growth in 2024
2024 holds promise for healthcare stocks, with Humana, Elevance, and others expected to boost earnings, as analysts say many industry pressures have been removed. 
Via MarketBeat
MarketBeat ‘Stock of the Week’: Intuitive Surgical hits new highs
With recent obesity drug fears proving to be overblown and equipment placements growing, expect ISRG to reward growth investors with plenty more record highs. 
Via MarketBeat
Topics Earnings
Exposures Financial
Insulet Announces Changes to Board of Directors with Retirements and New Appointments
From Insulet Corporation
Via Business Wire
Insulet to Announce Fourth Quarter and Full Year 2023 Financial Results on February 22, 2024
From Insulet Corporation
Via Business Wire
HCA Healthcare Rallies: Weight-loss drugs really a big threat?
HCA Healthcare rebounds amid concerns about weight-loss drugs' impact. The healthcare giant's revenue growth hints at resilience despite sector challenges. 
Via MarketBeat
Topics ETFs
Top Stock Picks For Week Of December 25, 2023
MoneyLion Inc. is a data-driven, digital financial platform. Insulet Corporation is a leading developer, manufacturer, and marketer of the Omnipod Insulin Management System. 
Via Talk Markets
Amazon.com To Rally Over 38%? Here Are 10 Top Analyst Forecasts For Thursday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.